Orion Corporation will publish its financial result for 2010 on Wednesday, 9 February 2011.
The publication dates of the Interim Reports in 2011 are as follows:
Interim Report 1-3/2011 Wednesday, 27 April 2011
Interim Report 1-6/2011 Tuesday, 2 August 2011
Interim Report 1-9/2011 Tuesday, 25 October 2011
Annual Report 2009 will be published during week 10/2011.
The Annual General Meeting is planned to be held on Thursday, 31 March 2011 in Helsinki.
Orion's financial reports and related presentation material are available on the Group's home pages at www.orion.fi/investors promptly after the publishing. The homepage also provides a possibility to register on Orion's mailing lists for publications and releases.
Timo Lappalainen Jari Karlson
President and CEO CFO
For additional information, kindly contact:
Susanna Siira, Investor Relations Manager, tel. +358 10 426 2782
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.